Red Light Therapy for Vaginal Atrophy: Evidence, Mechanisms and Best Devices

TL;DR

• Vaginal atrophy, formally known as genitourinary syndrome of menopause (GSM), affects an estimated 50% of postmenopausal women producing vaginal dryness, thinning of vaginal walls, painful intercourse, burning, and urinary symptoms. Unlike hot flushes, it worsens over time without treatment and is significantly undertreated.
• Photobiomodulation addresses vaginal atrophy through the same mechanisms that make it effective for skin rejuvenation: fibroblast activation and collagen synthesis in vaginal tissue, improved local microcirculation and natural lubrication, anti-inflammatory cytokine reduction, and mitochondrial energy restoration in atrophied mucosal cells.
• Published clinical research using intravaginal photobiomodulation probes has documented significant improvements. A 2025 first-in-human safety study of 25 patients found improvements in pain during intercourse (7.65 to 3.89, p less than 0.0001) and vaginal health index scores (12.68 to 17.63, p less than 0.0001).
• StreamShop devices are designed for external use only and are not intravaginal devices. External photobiomodulation targets the externally accessible vulvar tissue, labia, and perineal area - directly affected by GSM and accessible to full therapeutic irradiance from external devices.
• Red light therapy is best approached as a complementary tool alongside first-line GSM treatments including vaginal moisturisers, lubricants, and where appropriate, low-dose vaginal oestrogen or DHEA under medical guidance.

Vaginal atrophy is one of the most common and most undertreated consequences of menopause, affecting an estimated one in two postmenopausal women. Unlike the hot flushes of early menopause that often resolve over time, vaginal atrophy is progressive. Without treatment, oestrogen-depleted tissue continues to thin, lose elasticity, and produce less natural lubrication, making symptoms worsen rather than improve as the years after menopause accumulate.

Photobiomodulation has emerged as a promising non-hormonal approach to GSM, with a growing body of published clinical research and a mechanistic rationale directly relevant to the tissue changes that drive vaginal atrophy. This guide covers the biology of GSM, how photobiomodulation addresses it, what the research shows, the distinction between clinical intravaginal devices and external vulvar application, and how StreamShop devices can support vulvar tissue health as part of a broader GSM management approach.

Understanding Vaginal Atrophy and GSM

The term genitourinary syndrome of menopause (GSM) replaced the older terms vaginal atrophy and vulvovaginal atrophy in 2014, adopted by the International Society for the Study of Women's Sexual Health and the North American Menopause Society. GSM encompasses the vaginal, vulvar, and urinary symptoms that result from declining oestrogen levels after menopause.

When oestrogen levels fall, the vaginal walls become thinner and more fragile, dermal collagen supporting vaginal wall elasticity is progressively lost, reduced vascularisation decreases natural vaginal lubrication, and the labia minora may become thinner over time. GSM symptoms include vaginal dryness, burning, and irritation; painful intercourse (dyspareunia); reduced sexual desire and arousal; urinary urgency and frequency; and increased susceptibility to urinary tract infections. GSM is particularly significant after breast cancer treatment where hormonal therapies are frequently contraindicated.

How Photobiomodulation Addresses Vaginal Atrophy

Collagen Synthesis and Tissue Restoration

Red light at 630 to 660nm activates fibroblasts in the vaginal and vulvar dermis to upregulate collagen synthesis, producing new collagen fibres that restore tissue thickness, elasticity, and structural integrity. This is the same mechanism documented in skin rejuvenation applications and in the fractional CO2 laser treatments used clinically for GSM, though photobiomodulation achieves this through a non-ablative, non-thermal mechanism rather than through controlled tissue injury.

Improved Local Microcirculation and Lubrication

Nitric oxide released through cytochrome c oxidase activation causes vasodilation in the local microvasculature of vulvar and vaginal tissue. Improved blood flow increases the vascular transudate that is the primary source of vaginal lubrication. VEGF upregulation supports angiogenesis, rebuilding the vascular network in tissue where atrophy has reduced capillary density and directly addressing the lubrication deficit that is the most commonly reported GSM symptom.

Mitochondrial Restoration in Atrophied Mucosal Cells

Oestrogen deprivation reduces mitochondrial function in vaginal epithelial cells, contributing to the cellular energy deficit that accelerates tissue atrophy. Photobiomodulation restores cytochrome c oxidase function and ATP production, supporting the energy-intensive processes of epithelial cell renewal and tissue maintenance that decline with oestrogen loss. This is particularly relevant in the post-cancer setting where aromatase inhibitors compound the oestrogen-deprivation effect on vaginal tissue.

Anti-Inflammatory Effects

Chronic low-grade inflammation is increasingly recognised as a contributor to GSM pathology. Photobiomodulation reduces pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6, addressing this inflammatory component and reducing the discomfort and irritation that accompanies the structural tissue changes of GSM.

What the Published Research Shows

The Lanzafame 2019 Review: Mechanistic Foundation

A comprehensive 2019 review by Lanzafame, de la Torre, and Leibaschoff published in Photobiomodulation, Photomedicine and Laser Surgery (PMC6648197, DOI: 10.1089/photob.2019.4618) established the mechanistic rationale for photobiomodulation therapy specifically for GSM, concluding that based on preliminary evidence, PBMT is safe and appears to be efficacious in treating GSM.

The 2025 Salerno Safety Study

A 2025 prospective first-in-human medical device safety study published in Climacteric, conducted at CHU Nimes, University of Montpellier, enrolled 25 postmenopausal patients with pelvic pain due to vaginal atrophy after failure of non-invasive therapies. Patients received six weekly photobiomodulation sessions using a dedicated intravaginal probe. Pain during intercourse improved from 7.65 to 3.89 (p less than 0.0001) and vaginal health index scores improved from 12.68 to 17.63 (p less than 0.0001). No serious adverse effects were reported.

The 2025 PLOS ONE Prospective Study

A 2025 single-centre prospective study published in PLOS ONE enrolled 27 postmenopausal women with GSM and evaluated intravaginal 660nm photobiomodulation, finding improvements in both objective vaginal health index scores and subjective symptom measures. The authors concluded intravaginal 660nm PBM is a well-tolerated, non-hormonal modality that may improve objective vaginal health and subjective symptoms in GSM.

The French Interim Results: 130 Patients

Interim results from an ongoing French clinical study reported that 61 out of 100 GSM patients showed clinical improvement (better or much better) after 6 photobiomodulation sessions, with no serious adverse effects across 130 patients enrolled - the largest GSM photobiomodulation cohort reported to date.

The Placebo-Controlled Double-Blind Trial

A placebo-controlled double-blind trial (PMID 42060269) evaluated 808nm laser applied to eight vaginal points across four weekly sessions in postmenopausal women. The photobiomodulation group showed significant reduction in urinary incontinence alongside improvements in vaginal dryness and burning, concluding PBM appears to be a promising, non-invasive option for improving urinary symptoms and vaginal comfort in postmenopausal women.

The Honest Evidence Position

The published evidence base is growing and consistently positive, but most studies use dedicated intravaginal probe devices and have sample sizes of 25 to 27 participants. The US FDA has not cleared energy-based or light devices specifically for treating vaginal atrophy or GSM. First-line treatments remain vaginal moisturisers, lubricants, and where medically appropriate, low-dose vaginal oestrogen or intravaginal DHEA. Photobiomodulation is best positioned as a non-hormonal complementary approach with genuine mechanistic relevance and promising early clinical evidence.

External Vulvar Photobiomodulation vs Clinical Intravaginal Devices

The published clinical research uses dedicated intravaginal probe devices that deliver photobiomodulation directly to the vaginal mucosa internally. StreamShop devices are not intravaginal devices and are designed for external use only.

External photobiomodulation applied to the vulvar and perineal area targets the externally accessible anatomy: the vulva, labia majora and minora, clitoral hood, vaginal opening, and perineum. These external tissues are directly affected by GSM and experience the same collagen loss, reduced circulation, and mucosal changes as the internal vaginal canal. The vulvar tissue is directly accessible to external photobiomodulation at full therapeutic irradiance.

For women with predominantly external vulvar symptoms including vulvar dryness, irritation, and labial atrophy, external photobiomodulation is directly relevant. For women with predominantly internal symptoms including deep dyspareunia and internal vaginal dryness, clinical intravaginal devices or treatments administered by a healthcare provider address the internal anatomy more directly.

How to Use Red Light Therapy for Vaginal Atrophy

• Discuss with your GP or gynaecologist before starting. GSM management should be medically supervised.
• Never discontinue prescribed GSM treatments. Vaginal moisturisers, lubricants, and prescribed oestrogen or DHEA should continue as directed.
• External application to the vulvar area in a comfortable reclining position. Sessions of 10 to 20 minutes, three to five times per week.
• Use Red and near-infrared modes. Red + NIR mode (660nm + 850nm + 1064nm) for the deepest combination of surface collagen stimulation and tissue penetration.
• Consistency over 8 to 12 weeks is required for meaningful cumulative collagen and tissue restoration change.
• Cease use and consult your GP if you experience any irritation, unusual discharge, or discomfort.

StreamShop Devices for Vaginal Atrophy Support

LED Light Therapy Dome With 1064nm ($399.99)

StreamShop's LED light therapy dome with 1064nm delivers 660nm, 850nm, and 1064nm across 240 triple-chip LEDs in a 110cm x 28cm arch format with velcro fastening and wireless rechargeable remote. At 87.4 mW/cm² in Red + NIR mode, the dome provides the highest irradiance external vulvar coverage in the StreamShop range. The arch format curves naturally over the lower pelvis in a reclining position for completely hands-free coverage of the vulvar and perineal area without direct contact - the most practical option for women with acute vulvar sensitivity. Sessions of 10 to 20 minutes at P3 to P5 intensity are appropriate for external vulvar tissue applications.

Red Light Therapy Belt With 1064nm Laser ($299.99)

StreamShop's red light therapy belt with 1064nm laser delivers six wavelengths including 630nm, 660nm, 830nm, 850nm, 940nm, and 1064nm with 40 dedicated laser diodes at up to 164.5 mW/cm². Wrapping the belt around the lower pelvis positions the full six-wavelength array including 1064nm laser directly against external pelvic tissue for hands-free wearable sessions. The direct contact format is most practical for women without acute vulvar sensitivity during stable periods.

Portable Red Light Therapy Pad With Near-Infrared

StreamShop's portable red light therapy pad with near-infrared delivers 660nm and 850nm in a flexible wearable format. The pad conforms directly to the external vulvar and perineal area, maintaining consistent contact during sessions, and is comfortable for extended use in a reclining position.

Frequently Asked Questions

Can Red Light Therapy Help With Vaginal Atrophy?

Published clinical research using intravaginal photobiomodulation devices has documented significant improvements in vaginal health index scores, reduced pain during intercourse, and improved quality of life in postmenopausal women with GSM. External photobiomodulation to the vulvar area addresses the same collagen, circulation, and tissue health mechanisms in the externally accessible anatomy. Red light therapy is best approached as a complementary non-hormonal tool alongside established first-line GSM treatments under medical guidance.

What Is the Difference Between Clinical Intravaginal Devices and External Red Light Therapy for GSM?

Clinical intravaginal photobiomodulation probes deliver light directly to the internal vaginal mucosa. These are the devices used in published clinical research. External red light therapy devices including StreamShop's dome, belt, and portable pad are designed for external use only and target the externally accessible vulvar and perineal anatomy. External devices directly treat vulvar tissue but do not deliver light to the internal vaginal canal in the same way as intravaginal probes.

Is Red Light Therapy Safe for Vaginal Atrophy?

Published research consistently reports a favourable safety profile. The 2025 Salerno study of 25 patients reported no serious adverse effects. The French interim results across 130 patients reported no serious adverse effects. Red and near-infrared light is non-ionising and non-thermal at therapeutic doses, without the burn or scarring risks of ablative laser treatments. Always discuss with your GP before starting.

Can Red Light Therapy Help With Vaginal Dryness?

Vaginal dryness results from reduced vascularisation and epithelial thinning. Photobiomodulation improves local microcirculation through nitric oxide-mediated vasodilation and VEGF-supported angiogenesis, directly addressing the vascular component of lubrication deficit. Published research has documented improved lubrication as a secondary outcome alongside vaginal health index improvements.

Can Red Light Therapy Help With GSM After Breast Cancer Treatment?

GSM is particularly common and severe after breast cancer treatment where systemic oestrogen therapy is frequently contraindicated. Photobiomodulation is a non-hormonal approach with no hormonal mechanism, making it potentially relevant for breast cancer survivors where hormonal GSM treatments are restricted. Always discuss with your oncologist before starting.

How Long Before Red Light Therapy Shows Results for Vaginal Atrophy?

The collagen synthesis and tissue restoration mechanisms addressing GSM structural changes require consistent sustained use over 8 to 12 weeks to produce meaningful cumulative change, consistent with the six-week to three-month treatment protocols used in published clinical studies. Improved local circulation supporting lubrication may become noticeable earlier, within two to four weeks of consistent use, as vascular effects precede structural collagen changes.